Activity

This review provides a summary of recent results concerning the influence of cellular senescence (CS) on the progression of Alzheimer’s disease (AD), and further discusses the possible therapeutic impact of eliminating senescent cells for AD management.

A set of conditions, labeled channelopathies, is brought about by the impairment of ion channels or by a decrease in their surface expression on cells. Correcting the root cause necessitates the introduction and subsequent expression of a functional ion channel within the cell membrane of the targeted cell. Unfortunately, in the case of most channelopathies, current treatment approaches are typically aimed at alleviating symptoms, but therapies that address the fundamental cause of the disorder are currently lacking. In this context, gene and protein therapies are necessary approaches. Gene therapy’s promise of functional protein expression relies on the diseased cell’s ability to correctly fold and transport the protein to the cell membrane. Functional protein delivery via protein therapy is contingent upon a purification process that maintains protein integrity, and the availability of an appropriate delivery vehicle for targeted administration. We present an overview of channelopathies and their symptomatic treatments in this review. The discussion on gene therapy approaches, commonly using viral vectors, is followed by an analysis of nanomedicine’s involvement in protein therapy and its potential use for delivering functional ion channels to diseased cells.

Coronary artery disease (CAD) tragically holds the title of leading cause of morbidity and mortality in Western societies, despite progress in primary and secondary prevention strategies. Consequently, numerous novel biomarkers have been discovered as potential diagnostic and therapeutic targets, capable of enhancing outcomes, even when established risk factors are adequately managed. The pro-atherogenic, pro-thrombotic, and pro-inflammatory actions of lipoprotein (a) (Lp(a)) are accompanied by relatively constant levels, largely predetermined by genetics. Epidemiological research repeatedly demonstrates a correlation between elevated Lp(a) levels and a greater chance of developing acute coronary syndromes (ACS), even when other cardiovascular risk factors are considered in multivariable analyses. Despite a lack of specific therapeutic interventions for Lp(a) until recently, Lp(a) is now identified as a biomarker for risk and treatment modification. Intensified treatment of low-density lipoprotein (LDL) is recommended by current guidelines for patients with elevated Lp(a) and intermediate to high risk levels. Current advancements in Lp(a) treatment now include antisense oligonucleotides and small interfering RNAs, resulting in a substantial decrease in Lp(a) concentrations. The question of whether Lp(a) will be a specifically treated biomarker to reduce cardiovascular mortality hinges on the findings of the ongoing phase-3 trials. The present review article examines existing data regarding Lp(a) as a biomarker for increased CAD risk, along with future considerations for pharmaceutical approaches to reduce Lp(a) levels in high-risk individuals.

Circulating neurofilament light chain (NFL) levels in various dementia types were assessed diagnostically in this study.

Earlier research showcased fluctuating blood neurofilament light (NFL) levels across different forms of dementia, encompassing Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease dementia, Creutzfeldt-Jakob disease, and Lewy body dementia.

To improve the strength of the evidence, a meta-analysis was carried out to summarize the results of studies evaluating the diagnostic value of circulating NFL levels in various dementia types.

Articles on blood NFL levels and dementia, published before July 2022, were sought on the following databases: PubMed, Web of Science, EMBASE, Medline, and Google Scholar. STATA 120 software facilitated the derivation of the computed results.

A noteworthy increase in NFL concentration was detected in the serum and plasma of AD patients compared to healthy controls. The standard mean difference (SMD) was 109, the 95% confidence interval (CI) was 0.48 to 1.70, the I2 was 974%, and the p-value was less than 0.0001. Patients with AD showing higher neurofilament light chain (NFL) levels in serum and plasma demonstrated a corresponding reduction in cerebrospinal fluid (CSF) A1-42, an increase in CSF total tau (t-tau) and phosphorylated tau (p-tau), lower Mini-Mental State Examination (MMSE) scores, and a decline in memory performance. Serum and plasma neurofilament light chain (NFL) levels were demonstrably higher in mild cognitive impairment (MCI) participants in comparison to healthy controls (HC), with substantial statistical evidence (SMD = 0.53, 95% CI 0.18, 0.87, I² = 93.8%, p < 0.0001). No considerable correlation was noted between serum and plasma NFL levels and memory or visuospatial function in individuals with MCI. No substantial distinction was observed when contrasting preclinical Alzheimer’s Disease (AD) with healthy controls (HC), with a standardized mean difference of 0.18, a 95% confidence interval ranging from -0.10 to 0.47, an inconsistency index of 0.00%, and a p-value of 0.438. The serum and plasma of FTD patients showed a pronounced increase in NFL concentration, exhibiting a substantially higher level than healthy controls (SMD = 108, 95% CI 072, 143, I2 = 833%, p < 0001). Individuals with frontotemporal dementia demonstrated a connection between elevated NFL levels in their blood (serum and plasma) and elevated NFL levels in their cerebrospinal fluid. According to the pooled data, the parameters showed sensitivity to be 0.82 (95% confidence interval [0.72, 0.90]), and specificity to be 0.91 (95% confidence interval [0.83, 0.96]). CJD patients displayed a greater serum and plasma NFL concentration compared to the healthy controls, denoted as HC. The study found no meaningful difference in serum and plasma NFL levels between Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD) participants (SMD = -0.003, 95% CI -0.77 to 0.72, I² = 833%, p = 0.003).

The study’s findings, in closing, pointed to abnormal NFL blood levels in AD and MCI, but not in preclinical AD. Elevated NFL levels were observed in blood samples from patients with FTD and CJD.

The research’s conclusions suggest abnormal NFL blood levels in Alzheimer’s Disease and Mild Cognitive Impairment, but not in preclinical AD. Blood NFL levels displayed abnormalities in patients with FTD and CJD.

Repeated dermatological episodes, triggered by an autoimmune reaction, are indicative of psoriasis. In the worldwide population, a percentage, ranging between 2 and 3%, are affected by this autoimmune skin condition. This review aims to analyze and assess the effectiveness of established and nascent nanotechnological strategies in managing psoriasis, while also considering future directions. In order to compile the data for this review paper on psoriasis management using anti-psoriatic agents and nanotechnology, a thorough investigation was conducted across a wide range of online databases, such as ScienceDirect, Scopus, Google Scholar, ClinicalTrials.gov, Google Patents, ResearchGate, and PubMed. Keywords such as topical application, liposomal systems, niosomal systems, microneedle technology, clinical investigations, patents, the development of disease, biosimilar drugs, cytokines, and other significant concepts were explored in depth. Nano-technological approaches are rising in significance due to their capacity for precise delivery, rapid therapeutic effects, and minimized systemic impact. Researchers’ investigation into innovative, alternative therapeutic approaches for psoriatic conditions has shown them to be both secure and efficient. Beyond this, the potential contribution of many conventional psoriasis therapies has been investigated. Topical approaches to psoriasis treatment, as evidenced by granted and pending patents, have been the subject of significant exploration. Nanotechnology’s impact on pharmaceuticals is apparent in the improvement of physical, chemical, pharmacokinetic, and pharmacodynamic characteristics. Despite the comprehensive studies undertaken, a complete healing for psoriasis is impeded. An in-depth examination of the literature indicates that novel nanoparticle-based delivery approaches may augment pharmacological efficacy and eliminate or resolve issues linked to this ailment. The treatment of psoriasis via various drug delivery systems, alongside the status of clinical trials, patent applications and approvals, the commercialization of therapeutic agents, and the projected future of research, were all comprehensively reviewed.

The noticeable disease of HFMD, predominantly impacting children under five, creates a public health predicament for developing nations and the Asian Pacific region. Enterovirus 71 (EV71) and Coxsackievirus A16 are responsible for the development of this disease in many instances. HFMD, a mild febrile illness and general sickness, is usually present for about 10 days. Some risk factors comprise a young age, male gender, poor hygiene practices, and substantial social connections. A clinical diagnosis of HFMD relies on isolating the virus from both the stool and pharynx, and its visual confirmation via light microscopy. The gold standard for confirming viral presence from swabbed lesions is the Polymerase Chain Reaction Assay. Delayed confirmation of details might result in significant difficulties. No licensed treatments or vaccines exist for widespread use in addressing the diverse serotypes of hand, foot, and mouth disease. To effectively impede and regulate this condition, a crucial strategy entails strict obedience to the WHO’s complete set of eight guidelines.

Various bird species are susceptible to avian spirochetosis, a tick-borne bacterial infection. Symptoms associated with clinical conditions show considerable variation and are frequently nonspecific in nature. s1p receptor To ascertain the condition, the detection of the infectious spirochete is essential.